Replimune Group (NASDAQ:REPL) Trading Down 5.4% – Time to Sell?

Replimune Group, Inc. (NASDAQ:REPL) traded down 5.4% on Thursday . The company traded as low as $7.36 and last traded at $7.2950. Approximately 522,393 shares were traded during trading, a decline of 50% from the average session volume of 1,043,914 shares. The stock had previously closed at $7.71.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on REPL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, October 27th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research report on Monday, October 20th. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $3.00 to $13.00 in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Replimune Group Stock Performance

The company has a market cap of $552.22 million, a PE ratio of -2.03 and a beta of 0.72. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average of $9.35 and a 200-day moving average of $7.55.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,248 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the completion of the transaction, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of Replimune Group stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Readystate Asset Management LP boosted its position in shares of Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares in the last quarter. Braidwell LP lifted its position in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. boosted its holdings in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares in the last quarter. Erste Asset Management GmbH grew its position in shares of Replimune Group by 13,597.5% in the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after buying an additional 1,618,100 shares during the period. Finally, UBS Group AG increased its stake in shares of Replimune Group by 270.4% in the 3rd quarter. UBS Group AG now owns 901,630 shares of the company’s stock worth $3,778,000 after acquiring an additional 658,233 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.